RecruitingNot ApplicableNCT05377372

Early Life Exposures Among Children With Sickle Cell Disease

Sponsor

University of Alabama at Birmingham

Enrollment

20 participants

Start Date

Aug 1, 2026

Study Type

INTERVENTIONAL

Conditions

Sickle Cell Disease Breastfeeding Adverse Childhood Experiences

Summary

This study is being conducted to determine the relationship between early childhood exposures, such as Adverse Childhood Experiences, Social Determinants of Health and nutrition/breastfeeding, among children with sickle cell disease, and behavioral interventions aimed to reshape psychological resilience and lifestyle factors towards positive health outcomes.

Eligibility

Sex: FEMALEMin Age: 18 YearsMax Age: 50 Years

Plain Language Summary

Simplified for easier understanding

This clinical trial is studying a behavioral approach called Breastfeeding support group and Observation for people with adverse childhood experiences, breastfeeding, and other related conditions. The study is currently recruiting participants at 1 location. People eligible for this study include women aged 18 Years to 50 Years.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

BEHAVIORALBreastfeeding support group

community-based breastfeeding support group aimed to increase exclusive breastfeeding success rates among Black women

OTHERObservation

Observe prospectively for breastfeeding initiation, duration and longitudinal health of child with sickle cell disease

Locations(1)

University of Alabama at Birmingham

Birmingham, Alabama, United States

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT05377372

Related Trials

Blood Sampling for Research Related to Sickle Cell Disease

NCT005422301 location

A Study to Investigate the Efficacy and Safety of Crizanlizumab (5 mg/kg) Compared With Placebo in Adolescent and Adult Sickle Cell Disease Patients Who Experience Frequent Vaso-Occlusive Crises (SPARKLE)

NCT0643908232 locations